<p>艾尔希尔资本管理公司在最近向美国证券交易委员会的披露中表示，在第三季度将其在礼来公司的持股提高了 13.2%。该机构投资者在此期间额外购买了 1,134 股后，持有该公司 9,726 股股票。礼来公司大约占艾尔希尔资本管理公司投资组合的 3.4%，成为其第九大持仓。艾尔希尔资本管理公司在礼来公司的持股在最近一个季度末的价值为 7,421,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>FDA 批准诺和诺德的 Wegovy 药丸：2026 年的游戏规则改变者</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也增加或减少了在 LLY 的持股。住友三井金融集团在第二季度收购了价值约 27,000 美元的礼来公司新股份。Evolution Wealth Management 在第二季度购买了价值 29,000 美元的礼来公司新股份。Steph &amp; Co. 在第三季度将其在礼来公司的持股提高了 290.0%。Steph &amp; Co. 现在拥有 39 股该公司的股票，价值 30,000 美元，此前在此期间又购买了 29 股。Financial Gravity Companies 在第二季度收购了价值约 31,000 美元的礼来公司新股份。最后，Bare Financial Services 在第二季度将其在礼来公司的持股提高了 263.6%。Bare Financial Services 现在拥有 40 股该公司的股票，价值 31,000 美元，此前在此期间又购买了 29 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师升级和降级</h2>
<p>多家研究公司最近对 LLY 发布了报告。富国银行在 12 月 10 日的研究报告中将礼来公司的目标股价从 1,100.00 美元提高至 1,200.00 美元，并给予该公司 “超配” 评级。贝伦贝格银行在 12 月 2 日的报告中将礼来公司的目标股价从 830.00 美元提高至 950.00 美元，并给予该公司 “持有” 评级。古根海姆在 12 月 3 日的报告中重申了 “买入” 评级，并设定了 1,163.00 美元的目标股价。沃尔夫研究在 12 月 3 日的研究报告中将礼来公司的目标价从 1,050.00 美元提高至 1,250.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Erste Group Bank 在 10 月 14 日的报告中将礼来公司的评级从 “持有” 提升至 “买入”。四位研究分析师给予该股票 “强烈买入” 评级，十七位给予 “买入” 评级，五位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 1,155.36 美元。</p>
<ul>
<li>为什么华尔街放弃了辉瑞——这可能是个错误</li>
</ul>
<p><strong>获取我们关于礼来公司的最新研究报告</strong></p>
<h2>礼来公司股票下跌 0.4%</h2>
<p>礼来公司在周四的开盘价为 1,075.00 美元。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。该公司的 50 日移动平均价格为 1,003.00 美元，200 日移动平均价格为 846.93 美元。该股票的市值为 1.02 万亿美元，市盈率为 52.59，PEG 比率为 1.09，贝塔值为 0.37。该公司的速动比率为 1.24，流动比率为 1.55，债务股本比率为 1.71。</p>
<ul>
<li>礼来的新药数据为 2026 年设定了高风险赌注</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）在 10 月 30 日最后发布了季度财报。该公司报告季度每股收益为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。该业务在本季度的收入为 176 亿美元，而市场共识预期为 160.9 亿美元。在去年同期，该业务每股收益为 1.18 美元。礼来公司的季度收入同比增长 53.9%。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。作为一个整体，股票分析师预计礼来公司在当前年度将发布 23.48 的每股收益。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近还宣布了季度股息，将于 3 月 10 日支付。记录在案的股东将在 2 月 13 日获得每股 1.73 美元的股息。这代表着每年 6.92 美元的股息和 0.6% 的股息收益率。除息日期为 2 月 13 日。这是礼来公司之前每季度股息 1.50 美元的积极变化。礼来公司的股息支付比率目前为 29.35%。</p>
<h2>礼来公司公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区维持运营和商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官大卫·A 领导。</p>
<h2>另见</h2>
<ul>
<li>我们更喜欢的五只股票超过礼来公司</li>
<li>这个假期你花 1 美元能买到的最好东西</li>
<li>假期惊喜：1 美元让你拥有一切</li>
<li>美国 “最令人厌恶” 的圣诞促销</li>
<li>市场恐慌：特朗普刚刚对你的股票投下炸弹</li>
<li>你家族的财富在 2026 年到期？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Ayrshire Capital Management LLC 在第三季度将其在礼来公司（NYSE: LLY）的持股增加了 13.2%，目前持有 9,726 股，价值 742 万美元。这只股票占其投资组合的 3.4%。其他机构投资者也调整了在 LLY 的持仓。分析师对礼来的共识评级为 “适度买入”，目标价格为 1,155.36 美元。该公司报告了强劲的第三季度财报，盈利每股 7.02 美元，营收达到 176 亿美元，同比增长 53.9%</p>

<p>Ayrshire Capital Management LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 13.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,726 shares of the company's stock after acquiring an additional 1,134 shares during the period. Eli Lilly and Company makes up approximately 3.4% of Ayrshire Capital Management LLC's investment portfolio, making the stock its 9th largest position. Ayrshire Capital Management LLC's holdings in Eli Lilly and Company were worth $7,421,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>艾尔希尔资本管理公司在最近向美国证券交易委员会的披露中表示，在第三季度将其在礼来公司的持股提高了 13.2%。该机构投资者在此期间额外购买了 1,134 股后，持有该公司 9,726 股股票。礼来公司大约占艾尔希尔资本管理公司投资组合的 3.4%，成为其第九大持仓。艾尔希尔资本管理公司在礼来公司的持股在最近一个季度末的价值为 7,421,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 批准诺和诺德的 Wegovy 药丸：2026 年的游戏规则改变者</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $27,000. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the second quarter valued at $29,000. Steph &amp; Co. lifted its holdings in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph &amp; Co. now owns 39 shares of the company's stock worth $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company in the second quarter worth approximately $31,000. Finally, Bare Financial Services Inc lifted its position in shares of Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company's stock worth $31,000 after purchasing an additional 29 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也增加或减少了在 LLY 的持股。住友三井金融集团在第二季度收购了价值约 27,000 美元的礼来公司新股份。Evolution Wealth Management 在第二季度购买了价值 29,000 美元的礼来公司新股份。Steph &amp; Co. 在第三季度将其在礼来公司的持股提高了 290.0%。Steph &amp; Co. 现在拥有 39 股该公司的股票，价值 30,000 美元，此前在此期间又购买了 29 股。Financial Gravity Companies 在第二季度收购了价值约 31,000 美元的礼来公司新股份。最后，Bare Financial Services 在第二季度将其在礼来公司的持股提高了 263.6%。Bare Financial Services 现在拥有 40 股该公司的股票，价值 31,000 美元，此前在此期间又购买了 29 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>A number of research firms recently issued reports on LLY. Wells Fargo &amp; Company boosted their target price on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, December 10th. Berenberg Bank raised their target price on Eli Lilly and Company from $830.00 to $950.00 and gave the company a &#34;hold&#34; rating in a report on Tuesday, December 2nd. Guggenheim reiterated a &#34;buy&#34; rating and set a $1,163.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Wolfe Research raised their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 3rd. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, October 14th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $1,155.36.</p>
<div class="lb-trans"><p>多家研究公司最近对 LLY 发布了报告。富国银行在 12 月 10 日的研究报告中将礼来公司的目标股价从 1,100.00 美元提高至 1,200.00 美元，并给予该公司 “超配” 评级。贝伦贝格银行在 12 月 2 日的报告中将礼来公司的目标股价从 830.00 美元提高至 950.00 美元，并给予该公司 “持有” 评级。古根海姆在 12 月 3 日的报告中重申了 “买入” 评级，并设定了 1,163.00 美元的目标股价。沃尔夫研究在 12 月 3 日的研究报告中将礼来公司的目标价从 1,050.00 美元提高至 1,250.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Erste Group Bank 在 10 月 14 日的报告中将礼来公司的评级从 “持有” 提升至 “买入”。四位研究分析师给予该股票 “强烈买入” 评级，十七位给予 “买入” 评级，五位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 1,155.36 美元。</p>
</div><ul>
<li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么华尔街放弃了辉瑞——这可能是个错误</li>
</ul>
</div><p><strong>Get Our Latest Research Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>获取我们关于礼来公司的最新研究报告</strong></p>
</div><h2>Eli Lilly and Company Stock Down 0.4%</h2>
<div class="lb-trans"><h2>礼来公司股票下跌 0.4%</h2>
</div><p>LLY opened at $1,075.00 on Thursday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The company's 50-day moving average price is $1,003.00 and its two-hundred day moving average price is $846.93. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.59, a PEG ratio of 1.09 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.</p>
<div class="lb-trans"><p>礼来公司在周四的开盘价为 1,075.00 美元。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。该公司的 50 日移动平均价格为 1,003.00 美元，200 日移动平均价格为 846.93 美元。该股票的市值为 1.02 万亿美元，市盈率为 52.59，PEG 比率为 1.09，贝塔值为 0.37。该公司的速动比率为 1.24，流动比率为 1.55，债务股本比率为 1.71。</p>
</div><ul>
<li>Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来的新药数据为 2026 年设定了高风险赌注</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the business earned $1.18 earnings per share. Eli Lilly and Company's revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）在 10 月 30 日最后发布了季度财报。该公司报告季度每股收益为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。该业务在本季度的收入为 176 亿美元，而市场共识预期为 160.9 亿美元。在去年同期，该业务每股收益为 1.18 美元。礼来公司的季度收入同比增长 53.9%。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。作为一个整体，股票分析师预计礼来公司在当前年度将发布 23.48 的每股收益。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio is currently 29.35%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度股息，将于 3 月 10 日支付。记录在案的股东将在 2 月 13 日获得每股 1.73 美元的股息。这代表着每年 6.92 美元的股息和 0.6% 的股息收益率。除息日期为 2 月 13 日。这是礼来公司之前每季度股息 1.50 美元的积极变化。礼来公司的股息支付比率目前为 29.35%。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区维持运营和商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官大卫·A 领导。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>The Best $1 You'll Spend This Holiday Season</li>
<li>Holiday surprise: $1 gets you everything</li>
<li>America’s “most deplorable” Christmas sale</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
<li>Your family's wealth expires in 2026?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过礼来公司</li>
<li>这个假期你花 1 美元能买到的最好东西</li>
<li>假期惊喜：1 美元让你拥有一切</li>
<li>美国 “最令人厌恶” 的圣诞促销</li>
<li>市场恐慌：特朗普刚刚对你的股票投下炸弹</li>
<li>你家族的财富在 2026 年到期？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ayrshire Capital Management LLC 在礼来公司持有价值 742 万美元的股票头寸